PharmiWeb.com - Global Pharma News & Resources
08-May-2023

Pancreatic Cancer Drugs Global Market Report 2023: Featuring Bristol-Myers Squibb, Pfizer, AstraZeneca, F. Hoffmann-La Roche & Novartis - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Pancreatic Cancer Drugs Global Market Opportunities and Strategies to 2032" report has been added to ResearchAndMarkets.com's offering.


The global pancreatic cancer drugs market reached a value of nearly $3,872.5 million in 2022, having increased at a compound annual growth rate (CAGR) of 6.5% since 2017.

The market is expected to grow from $3,872.5 million in 2022 to $5,519.4 million in 2027 at a rate of 7.3%. The market is then expected to grow at a CAGR of 6.9% from 2027 and reach $7,720.1 million in 2032.

Growth in the historic period resulted from strong economic growth in emerging markets, an increasing aging population and an increasing prevalence of pancreatic cancer. Factors that negatively affected growth in the historic period were the high cost of drugs, low healthcare access in developing countries and the coronavirus pandemic.

Going forward, an increase in cancer incidence rates, a rise in healthcare expenditure and increasing government support will drive the market. Factors that could hinder the growth of the pancreatic cancer drugs market in the future include a rise in interest rates and the Russia- Ukraine war.

The pancreatic cancer drugs market is segmented by type into pancreatic neuroendocrine cancer drugs and pancreatic exocrine cancer drugs. The pancreatic neuroendocrine cancer drugs was the largest segment of the pancreatic cancer drugs market by type, accounting for $3,698.9 million or 95.5% of the total market in 2022. The pancreatic exocrine cancer drugs market is expected to be the fastest-growing segment going forward at a CAGR of 7.7%.

The pancreatic cancer drugs market is segmented by end-users into hospital pharmacies, retail pharmacies and other end-users. The hospital pharmacies market was the largest segment of the pancreatic cancer drugs market by end-users, accounting for $1,955.9 million or 50.5% of the total market in 2022. The retail pharmacies market is expected to be the fastest-growing segment going forward at a CAGR of 7.5%.

The pancreatic cancer drugs market is segmented by drug combination into single, double, triplet and quadruplet. The double was the largest segment of the pancreatic cancer drugs market by drug combination, accounting for $2,457.6 million or 63.5% of the total market in 2022. It is expected to be the fastest-growing segment going forward at a CAGR of 7.8%.

North America was the largest region in the pancreatic cancer drugs market, accounting for 40.7% of the global market in 2022. It was followed by Western Europe, Asia Pacific and the other regions. Going forward, the fastest growing regions in the pancreatic cancer drugs market will be the Middle East and South America, where growth will be at CAGRs of 13.5% and 10.8% respectively from 2022-2027.

The global pancreatic cancer drugs market is concentrated, with a large number of small players. The top ten competitors in the market made up to 61.17% of the total market in 2021. Bristol-Myers Squibb Company was the largest competitor with 11.94% share of the market, followed by Pfizer Inc. with 10.69%, AstraZeneca PLC with 10.17%, F. Hoffmann-La Roche AG with 9.07%, Novartis AG with 7.20%, Abbvie Inc. with 5.16%, Merck & Co., Inc. with 2.86%, Teva Pharmaceutical Industries with 2.00%, Amgen Incorporation with 1.42% and Eli Lilly and Company with 0.67%.

The top opportunities in the pancreatic cancer drugs market by type will arise in the pancreatic neuroendocrine cancer drugs market, which will gain $1,568.8 million of global annual sales by 2027. The top growth potential in the pancreatic cancer drugs market by end-users will arise in the hospital pharmacies market, which will gain $812.5 million of global annual sales by 2027. The top growth potential in the pancreatic cancer drugs market by drug combination will arise in the double market, which will gain $1,121.4 million of global annual sales by 2027. The pancreatic cancer drugs market size will gain the most in the USA at $461.5 million.

Market-trend-based strategies for the pancreatic cancer drugs market include focus on developing new drugs to treat pancreatic cancer, focus on novel nanomedicine treatment, focus on increasing investments, focus on strategic collaborations and focus on product innovations.

Player-adopted strategies in the pancreatic cancer drugs industry include enhancing business capabilities through strategic partnership and collaborations, focusing on providing targeted treatment options for pancreatic cancer patients through receiving regulatory approvals, strengthening business capabilities through partnerships and collaborations and enhancing business operations through securing regulatory approvals.

The report covers the following chapters

  • Introduction and Market Characteristics

Brief introduction to the segmentations covered in the market, definitions and explanations about pancreatic cancer drugs market.

  • Key Trends

Highlights the major trends shaping the global pancreatic cancer drugs market. This section also highlights likely future developments in the market.

  • Global Market Type and Growth

Global historic (2017-2022) and forecast (2022-2027), and (2027-2032) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods.

  • Regional Analysis

Historic (2017-2022) and forecast (2022-2027), and (2027-2032) market values and growth and market share comparison by region.

  • Market Segmentation

Contains the market values (2017-2032) and analysis for segment by drug combination, by type and by end-user in the market.

  • Regional Market Type and Growth

Regional market type (2022), historic (2017-2022) and forecast (2022-2027), and (2027-2032) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.

  • Competitive Landscape

Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.

  • Key Mergers and Acquisitions

Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years

  • Opportunities and Strategies -

This section gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.

  • Conclusions and Recommendations -

This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for pancreatic cancer drugs companies in terms of product offerings, geographic expansion, price offerings, and target groups.

  • Appendix -

This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Scope

Markets Covered:

1) By Type: Pancreatic Neuroendocrine Cancer Drugs; Pancreatic Exocrine Cancer Drugs

2) By Drug Combination: Single; Double; Triplet; Quadruplet

3) By End User: Hospital Pharmacies; Retail Pharmacies; Other End-Users

A selection of companies mentioned in this report includes

  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • AstraZeneca PLC
  • F. Hoffmann-La Roche AG
  • Novartis AG

For more information about this report visit https://www.researchandmarkets.com/r/k1a34s

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 08-May-2023